3-氨基-1-苯甲酰基氮杂啶 | 887588-62-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-氨基-1-苯甲酰基氮杂啶
• 英文名称: (3-Aminoazetidin-1-yl)(phenyl)methanone
• 英文别名: (3-aminoazetidin-1-yl)-phenylmethanone
• CAS: 887588-62-7
• 化学式: C₁₀H₁₂N₂O
• 分子量: 176.218
• InChiKey: UMVRSUKQZOUCCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  5-amino-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxylic acid 、 3-氨基-1-苯甲酰基氮杂啶 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 5-amino-N-(1-benzoylazetidin-3-yl)-3,4-dimethylthieno[2,3-c]pyridazine-6-carboxamide
  参考文献：
  名称：

  Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides

  摘要：

  This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c] pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The SAR to address potency, clearance, subtype selectivity, CNS exposure, and Pgp efflux are described. This work culminated in the discovery of VU6000918, which demonstrated robust efficacy in a rat amphetamine-induced hyperlocomotion reversal model at a minimum efficacious dose of 0.3 mg/kg. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.05.014
• 作为产物：
  描述：

  tert-butyl N-(1-benzoylazetidin-3-yl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 3-氨基-1-苯甲酰基氮杂啶
  参考文献：
  名称：

  Challenges in the development of an M 4 PAM preclinical candidate: The discovery, SAR, and in vivo characterization of a series of 3-aminoazetidine-derived amides

  摘要：

  This letter details the continued chemical optimization of a novel series of M4 positive allosteric modulators (PAMs) based on a 5-amino-thieno[2,3-c] pyridazine core by incorporating a 3-amino azetidine amide moiety. The analogs described within this work represent the most potent M4 PAMs reported for this series to date. The SAR to address potency, clearance, subtype selectivity, CNS exposure, and Pgp efflux are described. This work culminated in the discovery of VU6000918, which demonstrated robust efficacy in a rat amphetamine-induced hyperlocomotion reversal model at a minimum efficacious dose of 0.3 mg/kg. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2017.05.014

文献信息

• [EN] 2-PYRIDINE ALKYNE DERIVATIVES USEFUL FOR TREATING PAIN<br/>[FR] DERIVES DE 2-PYRIDINE ALKYNE SERVANT AU TRAITEMENT DE LA DOULEUR
  申请人：EURO CELTIQUE SA

  公开号：WO2005007641A1

  公开（公告）日：2005-01-27

  The invention provides a compound of formula (I): (where R1, Q, A and R2 are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Pyridine-alkynyl Compound”); pharmaceutical compositions comprising an effective amount of a Pyridine-alkynyl Compound; and methods for treating or preventing a condition such as pain, urinary incontinence, an addictive disorder, Parkinson’s disease, parkinsonism, anxiety, epilepsy, a seizure, stroke, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington’s chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Pyridine-alkynyl Compound.

  本发明提供了化合物式(I)的化合物：（其中R1，Q，A和R2在此披露）或其药学上可接受的盐（“吡啶-炔基化合物”）；包括有效量的吡啶-炔基化合物的制药组合物；以及治疗或预防动物的疼痛、尿失禁、成瘾障碍、帕金森病、帕金森综合症、焦虑、癫痫、癫痫发作、中风、瘙痒症、精神病、认知障碍、记忆缺陷、脑功能受限、亨廷顿舞蹈症、肌萎缩侧索硬化症、痴呆、视网膜病、肌肉痉挛、偏头痛、呕吐、运动障碍或抑郁症的方法，包括向需要治疗的动物中投与有效量的吡啶-炔基化合物。
• Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections
  申请人：Schmitz Franz Ulrich

  公开号：US20120121540A1

  公开（公告）日：2012-05-17

  Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).

  提供了某些化学实体、制药组合物和治疗方法，用于治疗黄病毒科的成员，例如丙型肝炎病毒（丙肝或HCV）。
• Certain nitrogen containing bicyclic chemical entities for treating viral infections
  申请人：Schmitz Franz Ulrich

  公开号：US20090176778A1

  公开（公告）日：2009-07-09

  Provided are certain chemical entities, pharmaceutical compositions, and methods of treatment of a member of the flaviviradae family of viruses such as hepacivirus (Hepatitis C or HCV).

  提供了某些化学实体、药物组合物和治疗方法，用于治疗黄病毒科家族成员，如丙型肝炎病毒（Hepatitis C或HCV）。
• NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS
  申请人：GENELABS TECHNOLOGIES, INC.

  公开号：EP2187883A2

  公开（公告）日：2010-05-26
• THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN
  申请人：Kyle Donald J.

  公开号：US20100256111A1

  公开（公告）日：2010-10-07

  The invention provides a compound of formula (I): (where R 1 , Q, A and R 2 are disclosed herein) or a pharmaceutically acceptable salt thereof (a “Pyridine-alkynyl Compound”); pharmaceutical compositions comprising an effective amount of a Pyridine-alkynyl Compound; and methods for treating or preventing a condition such as pain, urinary incontinence, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, a seizure, stroke, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a Pyridine-alkynyl Compound.